LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

44.79 -0.31

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.42

Max

44.86

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+22.57% upside

Turustatistika
By TradingEconomics
Turukapital	331M 3.6B
Eelmine avamishind	45.1
Eelmine sulgemishind	44.79

Uudiste sentiment

By Acuity

50%

156 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. dets 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26. dets 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26. dets 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26. dets 2025, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26. dets 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26. dets 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26. dets 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26. dets 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26. dets 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26. dets 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26. dets 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26. dets 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26. dets 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26. dets 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26. dets 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. dets 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26. dets 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26. dets 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26. dets 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26. dets 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25. dets 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25. dets 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25. dets 2025, 00:20 UTC

Omandamised, ülevõtmised, äriostud

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24. dets 2025, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24. dets 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. dets 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24. dets 2025, 19:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

24. dets 2025, 19:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24. dets 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

22.57% tõus

12 kuu keskmine prognoos

Keskmine 54.96 USD 22.57%

Kõrge 65 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

156 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.